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Abstract This critical opinion article deals with the
challenges of finding the most effective pharmacothera-
peutic options for the management of pain in intellectually
disabled children and provides recommendations for clin-
ical practice and research. Intellectual disability can be
caused by a wide variety of underlying diseases and may be
associated with congenital anomalies such as cardiac
defects, small-bowel obstructions or limb abnormalities as
well as with comorbidities such as scoliosis, gastro-eso-
phageal reflux disease, spasticity, and epilepsy. These
conditions themselves or any necessary surgical interven-
tions are sources of pain. Epilepsy often requires chronic
pharmacological treatment with antiepileptic drugs. These
antiepileptic drugs can potentially cause drug–drug inter-
actions with analgesic drugs. It is unfortunate that children
with intellectual disabilities often cannot communicate
pain to caregivers. Although these children are at high risk
of experiencing pain, researchers nevertheless often have to
exclude them from trials on pain management because of
ethical considerations. We therefore make a plea for pre-
scribers, researchers, patient organizations, pharmaceutical
companies, and policy makers to study evidence-based,
safe and effective pharmacotherapy in these children
through properly designed studies. In the meantime, par-
ents and clinicians must resort to validated pain assessment
tools such as the revised FLACC scale.
Key Points
The management of pain in intellectually disabled
children is challenging in view of the limited
possibilities for pain assessment, the high incidence
of comorbidities, and the use of co-medication.
Adequate pain assessment is the cornerstone of pain
management, and pain in intellectually disabled
children must be assessed with validated pain
assessment tools only.
Prescribers must be aware of the potential alterations
in pharmacokinetics and pharmacodynamics of
analgesics in intellectually disabled children, such as
drug–drug interactions with antiepileptic drugs.
Analysis of the pharmacokinetics of analgesics is
justified if large differences in effect or safety
between children with and without intellectual
disabilities can be expected.
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1 Introduction
The American Association on Intellectual and Develop-
mental Disabilities (AAIDD) defines intellectual disability
as ‘‘A disability characterized by significant limitations
both in intellectual functioning and in adaptive behavior,
which covers many everyday social and practical skills.
This disability originates before the age of 18’’ [1]. Intel-
lectual disability is associated with a wide variety of
underlying disorders, which are categorized into chromo-
somal abnormalities, single gene disorders, mitochondrial
disorders, and environmental disorders. Table 1 lists the
disorders in each of these categories; it is clear that the
group of intellectually disabled children is quite hetero-
geneous. The prevalence of severe intellectual disability
(IQ\ 50) across Europe varies from 3.0 to 5.1 per 1000
inhabitants [2]. Incidences of the various underlying dis-
orders vary widely, and Down syndrome is the most
common congenital anomaly underlying intellectual dis-
ability; in the Netherlands the incidence of Down syn-
drome is reported to be 14.57 per 10,000 births [3].
However, the cause of the intellectual disability cannot
always be identified [4]. Depending on the cause of the
intellectual disability, various areas of the brain involved in
the motivational-affective, cognitive-evaluative aspects of
pain, as well as autonomic responses to pain, can be
affected [5]. However, for children with birth asphyxia, it is
still unclear what the effect of the injury is on the different
aspects of the pain experience.
Many intellectually disabled children receive
antiepileptic drugs. Older antiepileptic drugs are known for
their enzyme inducing and inhibiting effects [6], and the
consequences of these effects on treatment with analgesic
drugs will be discussed below.
When John Langdon Down wrote his 1887 treatise on
what we now refer to as individuals with Trisomy 21, he
stated that ‘‘Common sensation is generally much less
acute than in ordinary persons. Pain is born with wonderful
callousness. It is not uncommon for children of this class to
allow a thecal abscess to be opened with a scalpel without a
grimace or without uttering a word’’ [7].
This passage perfectly describes the challenges care-
givers face when managing pain in intellectually disabled
children. Children with intellectual disabilities are often
unable to communicate pain to caregivers. Researchers will
therefore often exclude these children from trials on pain
management, and all the more so as inclusion would
involve special ethical considerations [8, 9]. That intel-
lectually disabled children often are excluded from
research is supported by the findings of Belew et al. that no
more than 0.03 % of the publications on pain in humans
addressed pain in intellectually disabled children [10].
The altered pain responses of children with intellectual
disabilities have been noted and, as a result, various
observational pain assessment tools have been developed
for this group. These tools will be discussed as in subse-
quent sections.
This critical opinion article deals with the challenges of
finding the most effective pharmacotherapeutic options for
the management of pain in intellectually disabled children
and provides recommendations for clinical practice and
research.
2 Pain Response
Pain responses in preverbal and nonverbal children may
vary on the basis of developmental differences, pain
experiences, and perhaps unknown genetic and hereditary
traits. In children with intellectual disabilities, the inter-
pretation of pain responses is even more complicated
because of the heterogeneity of underlying conditions,
children’s level of developmental delay, or the presence of
painful comorbidities. As these children often show
idiosyncratic behavior in response to pain, there is
Table 1 Underlying causes of intellectual disability
Category Examples of syndromes/disorders
Chromosomal
abnormalities
Down syndrome
Angelman syndrome
Prader–Willi syndrome
DiGeorge syndrome
Single gene disorders
X-linked disorders Fragile X syndrome
MECP2-related disorders (including Rett
syndrome)
Autosomal
dominant disorders
De novo mutations (i.e., STXPB1, SYGAP1,
SCN2A)
Autosomal
recessive disorders
PRSS12, CRBN, GRIK2
Mitochondrial
disorders
Leigh syndrome
MELAS (Mitochondrial encephalomyopathy
with lactate acidosis and stroke-like
episodes)
Environmental disorders
Prenatal causes Congenital infections
Environmental toxins or teratogens
Perinatal causes Preterm birth, hypoxia, infection, trauma,
intracranial hemorrhage
Postnatal causes Trauma, central nervous system hemorrhage,
hypoxia, toxins
Derived from Pivalizza P, Lalani SR. UpToDate: intellectual dis-
ability (mental retardation) in children: evaluation for a cause. Last
accessed: January 15 2015
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consensus among healthcare providers that parents are the
best informants of their child’s pain expression because
they know how their child expresses discomfort or comfort
in daily life [11]. That is valuable information when
dealing with the assessment of, for example, postoperative
pain in those children. With respect to chronic or persistent
pain, it is even more difficult to identify pain-related
behavior.
3 Adequate Pain Assessment
The International Association for the Study of Pain (IASP)
formulated the following definition of pain in 1979: ‘‘Pain
is an unpleasant sensory and emotional experience asso-
ciated with actual or potential tissue damage, or described
in terms of such damage’’ [12]. This definition still stands
today. Anand and Craig addressed in 1996 the limitations
of this definition, arguing that it is not applicable to indi-
viduals incapable of self-report such as infants, young
children, and intellectually disabled individuals [13]. In the
note that comes with the definition, IASP therefore later
added: ‘‘The inability to communicate verbally does not
negate the possibility that an individual is experiencing
pain and is in need of appropriate pain-relieving
treatment’’.
The ability to accurately measure pain is one of the
pillars in successful clinical pain management [14]. Self-
report is regarded as the gold standard for the measurement
of pain in children from the age of 4 years and in adults
[15]. Observational pain assessment, usually performed by
nurses, is considered the silver standard in children
younger than 4 years, sedated or mechanically ventilated
children, and intellectually disabled children.
Table 2 gives the available pain assessment instruments
validated for children with intellectual disabilities. They
vary from relatively simple and easy to use (Individualized
Numeric Rating Scale [INRS] and Revised Face, Legs,
Activity, Cry, Consolability [r-FLACC]) to more complex
such as the Paediatric Pain Profile (PPP). Other reviews
have provided details on the reliability and validity of the
instruments [16–18]. Inter-rater reliability of most of the
instruments is adequate, and construct validity—estimated
by correlating the outcomes of a new scale with those of an
existing scale—is sufficient [11, 19–21]. The lack of a gold
standard makes it impossible to determine real criterion
validity. The instruments have been primarily studied in a
hospital setting after surgery, with the exception of the
Non-Communicating Children’s Pain Checklist (NCCPC)
and PPP [19, 21, 22].
These instruments generally have been validated for
children from the age of 3 years and older, which is a
major reason why neonates and infants with developmentalT
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disabilities are an understudied group. We know that a
number of these children develop cerebral palsy later in
life, but currently we do not know how to assess their pain.
A study by Stevens et al. found that infants at risk for
neurological impairment showed a less intensive behav-
ioral response to heel lance than did infants with a low risk
for neurological impairment [23]. Our own group found
that the COMFORT behavior scale is also valid for the
detection of pain in neonates and infants with Down syn-
drome [24].
The available instruments primarily focus on behavioral
indicators of pain. Physicians, however, tend to prefer
physiological parameters for pain and distress assessment
[25]. Acute pain increases the heart rate and blood pressure
through the connections from the spinoreticular tract to the
brainstem and then further on to the sympathetic and
parasympathic efferent pathways. Nevertheless, heart rate
and blood pressure monitoring is not sensitive and specific
enough for the measurement of pain in the intensive-care
setting [26]. In some situations, however, for example
during general anesthesia, heart rate and blood pressure
monitoring is the only available measure of pain. This is
why bedside devices based on ‘objective surrogate’ mea-
sures have been developed, such as the Bispectral index
[27] to assess the level of consciousness, and skin con-
ductance [28] to assess distress and pain.
Unfortunately, Bispectral index monitoring of intellec-
tually disabled children is not reliable enough in clinical
practice since the values could be lower than in intellec-
tually unaffected children. This could lead to misinterpre-
tation of the state of consciousness [29]. The method of
measuring skin conductance is based on stress-induced
sweating of the palm of the hand and/or the soles of the feet
[30]. Sweat glands are stimulated by sympathetic excita-
tory efferent neurons and sweat is released within 1–2 s of
excitation, increasing the skin conductance because skin
resistance is then reduced. However, the technique for
measuring skin conductance needs to be improved and
standardized since studies give mixed results about the
sensitivity and specificity of this method for the measure-
ment of pain [31, 32].
A more recent study evaluated two other physiological
parameters for the detection of pain in children: heart rate
variability and pupillary reflex dilatation [33]. These two
parameters were measured during surgery in 58 children
between 2 and 16 years old. A rapid change in heart rate
variability and pupillary reflex dilatation was noted to
occur after skin incision when regional anesthesia failed
[33].
Another area of pain assessment is the analysis of sali-
vary cortisol levels and other biomarkers [34]. New, simple
techniques have been developed to determine cortisol
levels with the use of a smartphone app [35].
Treister et al. found that combining hemodynamic
parameters such as heart rate variability and skin conduc-
tance discriminated better between pain and no pain than
the single parameter approach [36]. Multimodal assessment
of pain in intellectually disabled children is certainly
worthy of study, because these are the patients who could
especially benefit from more advanced pain assessment
methods then having to rely on interpretation of their
behavior by caregivers.
4 Implementation and Knowledge Transfer
Six pain assessment instruments for children with intel-
lectual disabilities[3 years of age are available (Table 2).
The question is how often these are really used in daily
practice in hospitals and other facilities, bearing in mind
that pain management for children without intellectual
disabilities in pediatric settings still can be improved [37,
38]. One of the reasons is the existence of barriers to
regular pain assessment in hospitalized children; this has
been shown for the assessment of postoperative pain [39–
41]. Improving adherence to pain assessment can be
achieved by the availability of pain resource nurses [42]
and one-on-one coaching [43]. A large Canadian multi-
center study showed that pain management improved in
those settings where an Evidence-based Practice for
Improving Quality (EPIQ) approach toward pain manage-
ment was applied [44]. This involved efforts from external
pain experts and local facilitators. Seeing the great effort
needed to improve pain management for children without
intellectual disabilities, it is obvious that this is even more
difficult for children with intellectual disabilities. Pediatric
patients with intellectual disabilities will always form a
minority group and adherence to pain assessment with
these specific tools is hampered because they are not used
routinely. To the best of our knowledge, only one study has
described the implementation process of pain assessment
for children with intellectual disabilities, in a post-surgi-
cal/trauma unit and a rehabilitation unit [45]. Over a
4-month period, 30 children were eligible for inclusion.
The majority of nurses (93 % of 133 nurses) preferred the
r-FLACC over the PPP compared with 46 % of the 20
parents who participated. Six months after implementation,
use of the r-FLACC was evaluated; 37 of the 66 audited
patients (56.7 %) had indeed been assessed with the
r-FLACC. The authors concluded that to sustain a practice
change one needs to monitor the process and continue with
measures such as one-on-one training [45].
Although adequate pain assessment is the cornerstone of
pain management, the next step is prescribing adequate
analgesic agents with appropriate dosing instructions. In two
retrospective studies, intellectually disabled children in
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general received lower doses of intraoperative opioids com-
pared with controls [46, 47]. This practice might be due to
physicians’ perceptions about the patient’s sensitivity to pain
or response to analgesia. Malviya et al. reported that 89 % of
the physicians they surveyed tended to prescribe sub-thera-
peutic doses of analgesics to children with an intellectual
disability [48]. The authors considered lack of education and
knowledge as the primary barriers to effective pain manage-
ment in intellectually disabled children [48]. In a survey
among Dutch anesthesiologists on their pain management in
intellectually disabled children [49] around 90 % of the
respondents indicated theygive similar doses of intraoperative
opioids to intellectually and non-intellectually disabled chil-
dren, which is in stark contrast to the findings ofMalviya et al.
[48] a few years earlier. However, only 3 % of the anesthe-
siologists in the Dutch survey used a pain assessment instru-
ment validated for intellectually disabled children.
Changing erroneous perceptions of caregiverswith regard
to pain sensitivity and response to sedation of intellectually
disabled children is important since these perceptions could
influence analgesia and sedation practices [50]. This would
require training programs for pain specialists, collaboration
with physicians specialized in the care for intellectually
disabled individuals, and parent support groups. The relevant
organizations such as IASP and the American Society of
Anesthesiologists (ASA) should advocate for the develop-
ment and implementation of treatment guidelines and sup-
port knowledge transition. At an institutional level,
e-learning modules can be developed to train healthcare
professionals in pain assessment and management, and
stimulate them to adhere to the local guidelines.
5 Pain Resulting From Co-Morbidities
and Common Surgical Procedures
The following sections will illustrate the value of the pain
assessment instruments that have been developed for
intellectually disabled children, as they are at risk for pain
associated with co-morbidities and surgical procedures.
Early recognition and treatment can be key to preventing
the development of chronic pain. We know that around
15.4 % of intellectually disabled adults suffers from
chronic pain [51], the prevalence of chronic pain in chil-
dren with intellectual disabilities is unknown.
Two conditions are particularly relevant to intellectually
disabled children and will be discussed: gastro-esophageal
reflux disease and self-injurious behavior. Then for the two
bigger groups of intellectually disabled children, children
with Down syndrome and cerebral palsy, the most common
comorbidities and surgical procedures will be discussed.
Gastro-esophageal reflux disease is a major cause of
pain in intellectually disabled children [52]. It may be
associated with vomiting, pneumonia, and dental problems,
all of which are potentially painful [53]. Validated ques-
tionnaires are available to quantify symptom frequency and
severity of gastro-esophageal reflux [54]. Early detection
and early treatment of gastro-esophageal reflux is key to
preventing pain and other symptoms.
Thirteen percent of intellectually disabled individuals
show self-injurious behavior such as head banging or self-
biting, and pain could be a setting event for this behavior
(i.e., it is a way to express pain) [55]. The incidence of self-
injurious behavior in children with autism is reported to be
up to 50 %, but only in a small percentage with pain as a
setting event [56]. Algorithms for the assessment and
treatment of the self-injurious behavior have been devel-
oped; however, it remains a very challenging condition for
parents and healthcare professionals [56].
More than 80 different comorbidities have been associated
with Down syndrome [57], and some—such as a congenital
heart defect—are present in more than 40 % of children with
Down syndrome [58]. Up to 20 years ago, Down syndrome
was, at a number of institutions, a reason to withhold surgery
for congenital duodenal obstruction or congenital heart
defects [59]. This is no longer the case; surgery is offered
nowadays and, in combination with improved therapy for
pulmonaryhypertension and leukemia, the 10-year survival of
children with Down syndrome has improved to 91 % [60].
With reduced mortality, the morbidity is higher in those who
survive; therefore, adequate pain assessment andmanagement
is highly relevant in these children.
Cerebral palsy, on the other hand, is characterized by a
very wide variation in the severity of motor, sensory, and
neurological symptoms [61]. For example, intellectual
disability is not always present in children with cerebral
palsy, although they may show severe motor impairment.
The prevalence of recurrent pain in children with cerebral
palsy is 50–70 % [10]. The associated spasticity or other
musculoskeletal conditions such as scoliosis, muscle con-
tractures, and hip dislocations are potential causes of pain
[61]. These conditions require repetitive neurosurgical and
orthopedic procedures. Joint contractures and deformities
can cause entrapment of sensory and motor neurons and
consequently neuropathic pain; a pain condition that
requires a different approach. A small observational study
showed that this type of neuropathic pain was present in 11
(38 %) of individuals with cerebral palsy [62].
6 Altered Pharmacokinetics
and Pharmacodynamics and Co-Medication
It took quite some time before the determinants of devel-
opmental changes in infants and children on the pharma-
cokinetics of various drugs was recognized [63].
Pain in Intellectually Disabled Children 343
Nowadays, age- and weight-specific dosing recommenda-
tions are formulated for an increasing number of drugs
[63]. With regard to developmental pharmacokinetics of
analgesics, huge steps have been taken towards evidence-
based dosing of, for example, morphine in infants and
children [64].
The increasing interest in pharmacokinetics of anal-
gesics in intellectually disabled children is probably a
result of studies reporting differences in pharmacodynam-
ics between children with and without intellectual dis-
abilities. In two retrospective studies, intellectually
disabled children in general received lower doses of
intraoperative opioids compared with controls [46, 47].
Children with Down syndrome have been described as
more agitated and ‘‘difficult to sedate’’ after surgery [65].
One retrospective chart review study showed that children
with Down syndrome more often received sedatives and
muscle relaxants after cardiac surgery than children with-
out Down syndrome [66]. However, two other retrospec-
tive chart review studies did not show any differences in
analgesic requirements between the children with and
without Down syndrome [67, 68].
Since there are only a handful of pharmacological
studies on analgesics in intellectually disabled children,
other studies on the pharmacokinetics of other drugs in
intellectually disabled children will also be discussed here.
Interestingly, almost all those studies were performed in
individuals with Down syndrome, see Table 3. In general,
intellectually disabled children are more at risk of devel-
oping drug-related side effects [69, 70] and the related
signs may be more difficult to identify because history
taking might be more challenging. Special attention is
needed for drug–drug interactions with antiepileptic drugs,
since these drugs are often prescribed to intellectually
disabled children.
Looking at the pharmacokinetics of analgesics, the dis-
tribution and metabolism of paracetamol and morphine
have been studied in individuals with Down syndrome
(Table 3). Our own group performed a prospective trial on
the pharmacokinetics of intravenous morphine after cardiac
surgery in children with and without Down syndrome [71].
Population pharmacokinetic analysis revealed no statisti-
cally significant differences in the clearance or volume of
distribution of morphine in children with and without
Down syndrome. We concluded that there was no evidence
to adjust morphine dosing after cardiac surgery in children
with Down syndrome [71]. This brings us back to the
rationale for performing these pharmacokinetic studies,
which is the presumed difference in pharmacodynamics
between children with and without intellectual disabilities.
Epilepsy is a very common comorbidity in intellectually
disabled children. For example, up to 90 % of children
with Rett syndrome or Angelman syndrome suffer from
epilepsy [72], compared with 8 % of children with Down
syndrome [73]. Many intellectually disabled children will
therefore need lifelong treatment with antiepileptic drugs.
Older antiepileptic drugs (i.e., phenytoin, phenobarbital,
carbamazepine) may be expected to cause drug–drug
interactions, since they are potent inducers of multiple
cytochrome P450 enzymes [74]. The protein binding
effects and enzyme induction of these drugs on the phar-
macokinetics of sedative and analgesic drugs have been
described by Kofke [75]. Plasma concentrations of anal-
gesics and general anesthetics can either be increased or
decreased based on the type of antiepileptic drug. An
observational study found that adults who used
antiepileptic drugs needed higher doses of fentanyl for the
maintenance of general anesthesia than adults who did not
use antiepileptic drugs [76], a possible effect of hepatic
enzyme induction by the antiepileptic drugs. Newer
antiepileptic drugs such as gabapentin, lamotrigine, and
levetiracitam do not induce hepatic enzymes [6]. However,
for example in children with Rett syndrome, older
antiepileptic drugs such as sodium valproate,
Table 3 Findings of pharmacokinetic and pharmacodynamic studies in individuals with Down syndrome
Drug Pharmacokinetic findings Pharmacodynamic findings
Analgesics
Paracetamol [91] Metabolism increased to glutathione-
derived conjugates and decreased to the
sulfate-derived conjugates
Not investigated
Morphine [71] No differences in clearance or volume of
distribution
More oversedation in children with
Down syndrome
Other drugs
Sevoflurane [92, 93] Not investigated More bradycardia and hypotension
Methotrexate [94] Clearance 5 % lower in children with
Down syndrome
More toxicity
Theophylline [95] Clearance prolonged
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carbamazepine, and phenobarbital are still first-line agents
and clinicians should therefore be aware of the enzyme
inducing and inhibiting properties of these drugs [77].
Since these drugs are broad-spectrum inducers, pharma-
cokinetic studies on analgesics (such as fentanyl or mor-
phine) can be justified in children requiring long-term
treatment with these antiepileptic drugs.
7 Use of Novel Strategies in Pharmacological
Research
How can pharmacological studies improve pain manage-
ment in intellectually disabled children? Knowledge of
pharmacokinetics of drugs is required for the development
of model-based dosing regimens. We have shown that
more knowledge on drug–drug interactions is required, that
children with intellectual disabilities are more at risk for
side effects, and that the pharmacodynamics can be altered
in various groups of intellectually disabled children.
New sampling methods have improved the feasibility of
pediatric pharmacokinetic studies, as smaller blood vol-
umes and fewer samples are required for analysis [78].
Furthermore, opportunistic sampling (i.e., when a sample is
taken for clinical purposes, a little of the volume is used for
analysis of the level of drugs) has now been accepted by
the regulatory bodies [79].
Data from population pharmacokinetic and pharmaco-
dynamic studies can be used for simulations. These simu-
lations then can form the basis for the design of ‘proof-of-
principle’ studies, preferably randomized controlled trials
[80]. This approach has successfully been applied in neo-
nates, infants, and children without intellectual disability
(e.g., for midazolam, morphine and paracetamol) [81–83].
A perfect example is the dosing recommendation for the
use of propofol in children during correction of idiopathic
scoliosis [84]. The pharmacokinetic results were added to a
larger dataset and using population pharmacokinetic
methods, the clearance of propofol could be predicted and
subsequently a dosing recommendation could be made. A
reasonably small sample size is required for those studies
and therefore it is feasible to perform those studies in small
groups of intellectually disabled children [78].
Given the wide variety of causes of intellectual dis-
ability, comorbidities, and co-medication in these children,
it is not easy to set up large-scale pharmacological trials.
‘Model’ drugs can be used for classes of drugs metabolized
by the same enzymes of the cytochrome P450 system and
other metabolic pathways. This system approach renders
great opportunities for future pharmacological studies.
Systematic and careful monitoring of multimodal phar-
macodynamic outcome parameters could be a starting point
[85], preferably with a more advanced bedside device that
combines, for example, heart rate variability with skin
conductance measurements. Analysis of the pharmacoki-
netics is justified when a large difference in effect or safety
in children with and without intellectual disabilities can be
expected. These pharmacokinetic analyses would also be
useful when pharmacokinetic variability is presumed to be
related to the intellectual disability.
8 Conclusion
Intellectually disabled children are often excluded from
pain research because of their inability to self-report pain,
the variability in intellectually disability, ethical consider-
ations with regard to informed consent, unknown and
potential altered pharmacokinetics of analgesics, and use of
co-medication. Seeing that they are at high risk for acute
and chronic pain and often require more surgical inter-
ventions, there is every reason to optimize the pain man-
agement for intellectually disabled children. The ultimate
goal is to predict the amount of acute and chronic pain after
surgery, and thus the analgesia or sedation requirements,
leading to safe and effective pain management.
We therefore make a plea for prescribers, researchers,
patient organizations, pharmaceutical companies, and pol-
icy makers to study evidence-based and effective phar-
macotherapy in these children in properly designed trials.
In the meantime, parents and clinicians must resort to
validated pain assessment instruments, and preferably the
r-FLACC score. Hospitals and other healthcare institutions
are recommended to invest in implementation of the pain
assessment tools in clinical practice and in education of
caregivers and parents.
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